Skip to main content
Top
Published in: BMC Medicine 1/2021

01-12-2021 | COVID-19 | Research article

Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis

Authors: Saskia Ricks, Emily A. Kendall, David W. Dowdy, Jilian A. Sacks, Samuel G. Schumacher, Nimalan Arinaminpathy

Published in: BMC Medicine | Issue 1/2021

Login to get access

Abstract

Background

Testing plays a critical role in treatment and prevention responses to the COVID-19 pandemic. Compared to nucleic acid tests (NATs), antigen-detection rapid diagnostic tests (Ag-RDTs) can be more accessible, but typically have lower sensitivity and specificity. By quantifying these trade-offs, we aimed to inform decisions about when an Ag-RDT would offer greater public health value than reliance on NAT.

Methods

Following an expert consultation, we selected two use cases for analysis: rapid identification of people with COVID-19 amongst patients admitted with respiratory symptoms in a ‘hospital’ setting and early identification and isolation of people with mildly symptomatic COVID-19 in a ‘community’ setting. Using decision analysis, we evaluated the health system cost and health impact (deaths averted and infectious days isolated) of an Ag-RDT-led strategy, compared to a strategy based on NAT and clinical judgement. We adopted a broad range of values for ‘contextual’ parameters relevant to a range of settings, including the availability of NAT and the performance of clinical judgement. We performed a multivariate sensitivity analysis to all of these parameters.

Results

In a hospital setting, an Ag-RDT-led strategy would avert more deaths than a NAT-based strategy, and at lower cost per death averted, when the sensitivity of clinical judgement is less than 90%, and when NAT results are available in time to inform clinical decision-making for less than 85% of patients. The use of an Ag-RDT is robustly supported in community settings, where it would avert more transmission at lower cost than relying on NAT alone, under a wide range of assumptions.

Conclusions

Despite their imperfect sensitivity and specificity, Ag-RDTs have the potential to be simultaneously more impactful, and have a lower cost per death and infectious person-days averted, than current approaches to COVID-19 diagnostic testing.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organisation. WHO COVID-19 Preparedness and Response Progress Report - 1 February to 30 June 2020. Geneva: WHO; 2020. World Health Organisation. WHO COVID-19 Preparedness and Response Progress Report - 1 February to 30 June 2020. Geneva: WHO; 2020.
2.
go back to reference Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic testing for severe acute respiratory syndrome–related coronavirus-2. Ann Internal Med. 2020; M20–1301. Available from: doi:https://doi.org/10.7326/M20-1301. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic testing for severe acute respiratory syndrome–related coronavirus-2. Ann Internal Med. 2020; M20–1301. Available from: doi:https://​doi.​org/​10.​7326/​M20-1301.
3.
11.
go back to reference World Health Organisation. COVID-19 target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0. Geneva: WHO; 2020. World Health Organisation. COVID-19 target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0. Geneva: WHO; 2020.
14.
go back to reference World Health Organisation. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Geneva: WHO; 2020. World Health Organisation. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Geneva: WHO; 2020.
22.
go back to reference Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med. 2020;18(346). Available from. https://doi.org/10.1186/s12916-020-01810-8. Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med. 2020;18(346). Available from. https://​doi.​org/​10.​1186/​s12916-020-01810-8.
23.
go back to reference Hellou MM, Górska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;S1198-743X(20): 30695–30699. Available from: doi:https://doi.org/10.1016/j.cmi.2020.11.002. Hellou MM, Górska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;S1198-743X(20): 30695–30699. Available from: doi:https://​doi.​org/​10.​1016/​j.​cmi.​2020.​11.​002.
30.
31.
go back to reference World Health Organisation. Q&A: Dexamethasone and COVID-19. Geneva: WHO; 2020. World Health Organisation. Q&A: Dexamethasone and COVID-19. Geneva: WHO; 2020.
33.
go back to reference Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15): 458–464. Available from: doi:https://doi.org/10.15585/mmwr.mm6915e3. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15): 458–464. Available from: doi:https://​doi.​org/​10.​15585/​mmwr.​mm6915e3.
36.
go back to reference Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health. 2020;17(20): 7560. Available from: doi:https://doi.org/10.3390/ijerph17207560. Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health. 2020;17(20): 7560. Available from: doi:https://​doi.​org/​10.​3390/​ijerph17207560.
38.
39.
go back to reference Stuart A, Ord K, Arnold S. Partial and multiple correlation. Kendall’s Advanced Theory of Statistics, Volume 2A, Classical Inference and the Linear Model. 6th ed. 2010. Stuart A, Ord K, Arnold S. Partial and multiple correlation. Kendall’s Advanced Theory of Statistics, Volume 2A, Classical Inference and the Linear Model. 6th ed. 2010.
Metadata
Title
Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis
Authors
Saskia Ricks
Emily A. Kendall
David W. Dowdy
Jilian A. Sacks
Samuel G. Schumacher
Nimalan Arinaminpathy
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-021-01948-z

Other articles of this Issue 1/2021

BMC Medicine 1/2021 Go to the issue